CHAPTER 6 154 Molecular POLEmut 27 (8.9) 3 (7.5) 15 (16.0) 0 (0.0) 22 (8.4) MMRd 65 (21.3) 14 (35.0) 34 (35.2) 14 (37.8) 77 (29.3) P53mut 32 (10.5) 11 (27.5) 25 (26.6) 8 (21.6) 78 (29.7) NSMP 181 (59.3) 12 (30.0) 20 (21.3) 15 (40.5) 86 (32.7) MI <50% 191 (62.6) 26 (65.0) 19 (20.2) 19 (51.4) 145 (55.1) >50% 114 (37.4) 14 (35.0) 75 (79.8) 18 (48.6) 111 (42.2) Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (2.7) LVSI No 52 (17.0) 11 (27.5) 9 (9.6) 3 (8.1) 149 (56.7) Yes 253 (83.0) 29 (72.5) 85 (90.4) 34 (91.9) 114 (43.3) Lymph nodes N0 164 (53.8) 9 (22.5) 47 (50.0) 11 (29.7) 0 (0.0) N1 19 (6.2) 4 (10.0) 31 (33.0) 0 (0.0) 0 (0.0) Nx 122 (40.0) 27 (67.5) 16 (17.0) 26 (70.3) 263 (100.0) FIGO stage Early (I-II) 270 (88.5) 31 (77.5) 40 (42.6) 37 (100.0) 180 (68.4) Advanced (III-IV) 35 (11.5) 9 (22.5) 54 (57.4) 0 (0.0) 78 (29.7) Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (1.9) Adjuvant treatment None 122 (40.0) 24 (60.0) 1 (1.1) 18 (48.6) 122 (46.4) Radiotherapy 153 (50.2) 11 (27.5) 30 (31.9) 19 (51.4) 34 (12.9) Chemotherapy 10 (3.3) 3 (7.5) 29 (30.9) 0 (0.0) 35 (13.3) Chemoradiation 20 (6.6) 2 (5.0) 34 (36.2) 0 (0.0) 66 (25.1) Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (2.3) Table S1. Continued
RkJQdWJsaXNoZXIy MTk4NDMw